Masami MUKAI

Ms. Masami MUKAI

National Cancer Centre, Tokyo, Japan
+1
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 March 2022 in JMIR Human Factors
Verified
Journal Article
Open access
HTHonoka Tamori
Honoka Tamori
HYHiroko YAMASHINA
Hiroko YAMASHINA
MMMasami MUKAI
Masami MUKAI
YMYasuhiro Morii
Yasuhiro Morii
TSTeppei Suzuki
Teppei Suzuki
KOKatsuhiko Ogasawara
Katsuhiko Ogasawara
Background: The use of artificial intelligence (AI) in the medical industry promises many benefits, so AI has been introduced to medical practice primarily in developed countries. In Japan, the government is preparing for the rollout of AI in the medical industry. This rollout depends on doctors and the public accepting the technology. Therefore it is necessary to consider acceptance among doctors and among the public. However, little is known about the acceptance of AI in medicine in Japan. Objective: This study aimed to obtain detailed data on the acceptance of AI in medicine by comparing the acceptance among Japanese doctors with that among the Japanese public. Methods: We conducted an online survey, and the responses of doctors and members of the public were compared. AI in medicine was defined as the use of AI to determine diagnosis and treatment without requiring a doctor. A questionnaire was prepared referred to as the unified theory of acceptance and use of technology, a model of behavior toward new technologies. It comprises 20 items, and each item was rated on a five-point scale. Using this questionnaire, we conducted an online survey in 2018 among 399 doctors and 600 members of the public. The sample-wide responses were analyzed, and then the responses of the doctors were compared with those of the public using t tests. Results: Regarding the sample-wide responses (N=999), 653 (65.4%) of the respondents believed, in the future, AI in medicine would be necessary, whereas only 447 (44.7%) expressed an intention to use AI-driven medicine. Additionally, 730 (73.1%) believed that regulatory legislation was necessary, and 734 (73.5%) were concerned about where accountability lies. Regarding the comparison between doctors and the public, doctors (mean 3.43, SD 1.00) were more likely than members of the public (mean 3.23, SD 0.92) to express intention to use AI-driven medicine (P<.001), suggesting that optimism about AI in medicine is greater among doctors compared to the public. Conclusions: Many of the respondents were optimistic about the role of AI in medicine. However, when asked whether they would like to use AI-driven medicine, they tended to give a negative response. This trend suggests that concerns about the lack of regulation and about accountability hindered acceptance. Additionally, the results revealed that doctors were more enthusiastic than members of the public regarding AI-driven medicine. For the successful implementation of AI in medicine, it would be necessary to inform the public and doctors about the relevant laws and to take measures to remove their concerns about them.

11 June 2024 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
SKSyuzo Kaneko
Syuzo Kaneko
KTKen Takasawa
Ken Takasawa
KAKen Asada
Ken Asada
KSKouya Shiraishi
Kouya Shiraishi
NINoriko Ikawa
Noriko Ikawa
Ryuji HamamotoRyuji Hamamoto
Ryuji Hamamoto
Background: In an extensive genomic analysis of lung adenocarcinomas (LUADs), driver mutations have been recognized as potential targets for molecular therapy. However, there remain cases where target genes are not identified. Super-enhancers and structural variants are frequently identified in several hundred loci per case. Despite this, most cancer research has approached the analysis of these data sets separately, without merging and comparing the data, and there are no examples of integrated analysis in LUAD. Methods: We performed an integrated analysis of super-enhancers and structural variants in a cohort of 174 LUAD cases that lacked clinically actionable genetic alterations. To achieve this, we conducted both WGS and H3K27Ac ChIP-seq analyses using samples with driver gene mutations and those without, allowing for a comprehensive investigation of the potential roles of super-enhancer in LUAD cases. Results: We demonstrate that most genes situated in these overlapped regions were associated with known and previously unknown driver genes and aberrant expression resulting from the formation of super-enhancers accompanied by genomic structural abnormalities. Hi-C and long-read sequencing data further corroborated this insight. When we employed CRISPR-Cas9 to induce structural abnormalities that mimicked cases with outlier ERBB2 gene expression, we observed an elevation in ERBB2 expression. These abnormalities are associated with a higher risk of recurrence after surgery, irrespective of the presence or absence of driver mutations. Conclusions: Our findings suggest that aberrant gene expression linked to structural polymorphisms can significantly impact personalized cancer treatment by facilitating the identification of driver mutations and prognostic factors, contributing to a more comprehensive understanding of LUAD pathogenesis.

4 July 2022 in Healthcare
Verified
Journal Article
Open access
PDF file
MMMasami MUKAI
Masami MUKAI
KOKatsuhiko Ogasawara
Katsuhiko Ogasawara
Many medical information standards are not widely used in Japan, and this hinders the promotion of the use of real-world data. However, the complex intertwining of many factors hindering the dissemination of medical information standards makes it difficult to solve this problem. This study analyzed and visualized relationships among factors that inhibit the dissemination of medical information standards. Five medical informatics experts affiliated with universities and hospitals were interviewed about the factors that hinder the dissemination of medical information standards in Japan. The presented factors were analyzed using the interpretive structural modeling (ISM) method and the decision-making trial and evaluation laboratory (DEMATEL) method. We found that “legislation” and “reliability” were important inhibiting factors for the dissemination of medical information standards in Japan. We also found a six-layered structure in which “reliability” was satisfied when “legislation” was in place and “expectations” and “personal information” were resolved. The DEMATEL analysis indicated the relationships and classifications of factors hindering the dissemination of medical information standards. Since the adoption of medical information standards does not directly lead to revenue for medical institutions, it is possible to meet the “expectation” of improving the quality of medical care by ensuring “legislation” and “reliability”, that is, ensuring the dependability of medical treatment. The results of this study visually show the structure of the factors and will help solve the problems that hinder the effective and efficient spread of standards. Solving these problems may support the efficient use of real-world data.

18 November 2024 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
TTTakeshi Takamoto
Takeshi Takamoto
SNSatoshi Nara
Satoshi Nara
DBDaisuke Ban
Daisuke Ban
TMTakahiro Mizui
Takahiro Mizui
MMMasami MUKAI
Masami MUKAI
KSKazuaki Shimada
Kazuaki Shimada

1 May 2024 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
TTTakeshi Takamoto
Takeshi Takamoto
SNSatoshi Nara
Satoshi Nara
DBDaisuke Ban
Daisuke Ban
TMTakahiro Mizui
Takahiro Mizui
MMMasami MUKAI
Masami MUKAI
KSKazuaki Shimada
Kazuaki Shimada

25 August 2025 in Lung Cancer
Verified
Journal Article
Open access
ATAkiko Tateishi
Akiko Tateishi
HHHidehito Horinouchi
Hidehito Horinouchi
NKNobuji Kouno
Nobuji Kouno
KTKatsuji Takeda
Katsuji Takeda
KTKen Takasawa
Ken Takasawa
RHRyuji Hamamoto
Ryuji Hamamoto
Integrated recurrence prediction models that combine clinical, imaging, and genetic data are lacking for epidermal growth factor receptor (EGFR)-mutated stage I non-small cell lung cancer (NSCLC). We developed a recurrence prediction model for Stage I EGFR-mutated NSCLC by integrating clinical, radiological, and whole-exome sequencing (WES) data. A total of 306 patients with Stage I EGFR-mutated NSCLC were stratified into training (n = 206) and validation (n = 100) cohorts using stratified random sampling. Cox proportional hazards models combined binary labels of clinical and radiological factors from univariate analysis, machine-learning-derived MultiGenes labels (determined by multiple gene mutations) from WES data, and high-impact gene mutations. Predictive performance was assessed using the concordance index (C-index), time-dependent area under the curve (AUC), and receiver operating characteristic curves. The top three models by category were evaluated using a survival analysis. Three optimal models were identified; the clinicoradiological model (Model 17) achieved a C-index of 0.70, the model incorporating clinicoradiological factors and MultiGenes (Model 28) achieved 0.69, and the clinicoradiological model with TP53 mutations (Model 39) demonstrated the best performance, with 0.73. In Model 17, the 60-month recurrence-free survival (RFS) rates were 59.1 % for the high-risk group and 83.2 % for the low-risk group (hazard ratio [HR] = 3.47; 95 % confidence interval [CI]: 1.60-8.00). Model 39, which incorporated TP53 mutations, demonstrated superior performance, with 60-month RFS rates of 57.1 % for the high-risk and 87.1 % for the low-risk groups (HR = 4.79; 95 %CI: 1.96-11.69). Clinical and radiological factors are effective predictors of recurrence risk in Stage I EGFR-mutated NSCLC, and incorporating TP53 mutation data further improves the prognostic accuracy.